Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 3 of 13, showing 5 Applications out of 64 total, starting on record 11, ending on 15

# Protocol No Study Title Investigator(s) & Site(s)

11.

ECCT/15/04/02  
    Plasma concentration profiles after oral  administration of oleylphosphocholine tablet  formulation: safety, tolerability and pharmacokinetics  of 100 mg single dose in healthy male volunteers.   
Principal Investigator(s)
1. Ravasco Rashid Juma
Site(s) in Kenya
KEMRI
 
View

12.

ECCT/17/08/05   Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection.
    Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection.   
Principal Investigator(s)
1. Isaac Tsikhutsu
Site(s) in Kenya
Kenya Medical Research Institute/Walter Reed Project HIV Program, Kericho
 
View

13.

ECCT/23/09/05   LCCC 2236 Study
    LCCC  2236: Phase I study of self-administered Artesunate pessaries (vaginal inserts) for treatment of cervical precancer in HIV positive and HIV-negative women in Kenya    
Principal Investigator(s)
1. Chemtai Mungo
2. Jackton Omoto
Site(s) in Kenya
FACES, Lumumba Sub-county Hospital
 
View

14.

ECCT/26/04/02   IGHID 12430/DELIVER-02
    IGHID12430/DELIVER-02 - A PHASE 1, OPEN LABEL,STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MGD014 AND MGD020 WITH A LATENCY REVERSAL AGENT VERSUS TEMPORARY TREATMENT INTERRUPTION IN PERSONS WITH HIV-1 ON ANTIRETROVIRAL THERAPY   
Principal Investigator(s)
1. Charity Wambui Kanyoro
Site(s) in Kenya
1. Moi University Clinical Research Centre(MUCRC), Eldoret, Kenya (Uasin Gishu county)
2. Kericho Clinical Research Center (Kericho CRC), Kericho, (Kericho county)
 
View

15.

ECCT/25/11/02   DELIVER-02
    IGHID 12430/DELIVER-02 - A PHASE 1, OPEN LABEL,STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MGD014 AND MGD020 WITH A LATENCY REVERSAL AGENT VERSUS TEMPORARY TREATMENT INTERRUPTION IN PERSONS WITH HIV-1 ON ANTIRETROVIRAL THERAPY   
Principal Investigator(s)
1. Deborah Chepngeno Langat
Site(s) in Kenya
1. Kericho Clinical Research Center (Kericho CRC), Kericho, (Kericho county)
2. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (MUCRC), ELDORET (Uasin Gishu county)
 
View